news

CUPERTINO, Calif., June 26, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 against the approval of REMOXY® ER (oxycodone extended-release capsules) for […]

CUPERTINO, Calif., May 9, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the “Amendment”) to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR® (SABER®-bupivacaine) in the United States.   DURECT received an upfront payment from Sandoz of $20 million at the

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., May 2, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.   Total revenues were $3.5 million and net loss was $8.3 million for the three months ended

CUPERTINO, Calif., April 25, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in diseases

CUPERTINO, Calif., April 24, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s(Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of

CUPERTINO, Calif., March 29, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time. The call will feature a presentation by KOL Paul Kwo, MD, who will present an overview of alcoholic

CUPERTINO, Calif., March 20, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended release oxycodone CII).  REMOXY® ER is designed as an

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 1, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2017 and provided a corporate update.   Total revenues were $19.5 million and net profit was $8.2 million for the three

CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several

CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast